Difamilast Ointment in Japanese Adult and Pediatric Patients with Atopic Dermatitis: A Phase III, Long-Term, Open-Label Study

Hidehisa Saeki, Tomomi Imamura, Daisuke Yokota, Hidetsugu Tsubouchi, Hidehisa Saeki, Tomomi Imamura, Daisuke Yokota, Hidetsugu Tsubouchi

Abstract

Introduction: Phosphodiesterase 4 (PDE4), which regulates inflammatory cytokine production leading to atopic dermatitis (AD), is selectively inhibited by difamilast. The objective of this phase III, long-term, open-label study was to evaluate the safety and efficacy of topical difamilast in Japanese adult and pediatric patients with AD.

Methods: Adult patients (n = 166) began treatment with difamilast 1% ointment, and pediatric patients began treatment with difamilast 0.3% ointment (n = 144) or difamilast 1% ointment (n = 56). Treatment was continued twice daily for 52 weeks. All patients had an Investigator's Global Assessment (IGA) score of 2 (mild), 3 (moderate), or 4 (severe/very severe), and an AD-affected body surface area (BSA) of ≥ 5% before treatment, with no restriction on the upper limit for the AD-affected BSA.

Results: During therapy, 120 adult patients (72.3%) and 178 pediatric patients (89.0%) experienced treatment-emergent adverse events (TEAEs), most of which were mild or moderate in severity. Discontinuation due to TEAEs was reported in 13 adult patients (7.8%) and in 7 pediatric patients (3.5%). Treatment-related adverse events were reported in 14 adult patients (8.4%) and 16 pediatric patients (8.0%), most frequently dermatitis atopic (1.8%) and acne (1.2%) in adult patients and dermatitis atopic and pigmentation disorder (each 2.0%) in pediatric patients. The cumulative success rates in Eczema Area and Severity Index (EASI)-75 in adult and pediatric patients were 55.4% and 73.5%, respectively, at week 52, and the cumulative success rates increased from week 4 to week 52. The cumulative success rates in IGA score showed the same trend as those in EASI -75.

Conclusions: This study demonstrates that difamilast ointments are well tolerated and effective in Japanese adult and pediatric patients with AD when applied twice daily for 52 weeks, and are expected to be used for a long-term treatment for AD.

Clinical trial registration: Clinical Trials.gov identifier: NCT03961529.

Keywords: Application; Atopic dermatitis; Difamilast; Japanese adult and pediatric patients; Ointment; Open-label study; Phosphodiesterase 4; Safety.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Cumulative success rate in Eczema Area and Severity Index (EASI)-75 a in adult patients (n = 166) and b in pediatric patients (n = 200). The data represent the cumulative percentage of patients achieving ≥ 75% improvement in overall EASI score from baseline

References

    1. Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol. 2018;19:319–332. doi: 10.1007/s40257-017-0335-4.
    1. Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233:333–343. doi: 10.1159/000484407.
    1. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: getting the itch out? Clin Rev Allergy Immunol. 2016;51:263–292. doi: 10.1007/s12016-015-8488-5.
    1. Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22:125–137. doi: 10.5021/ad.2010.22.2.125.
    1. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–1494. doi: 10.1056/NEJMra074081.
    1. Silverberg JI, Nelson DB, Yosipovitch G. Addressing treatment challenges in atopic dermatitis with novel topical therapies. J Dermatol Treat. 2016;27:568–576. doi: 10.1080/09546634.2016.1174765.
    1. Fahrbach K, Tarpey J, Washington EB, et al. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network meta-analysis. Dermatol Ther (Heidelb) 2020;10:681–694. doi: 10.1007/s13555-020-00389-5.
    1. Hiyama H, Arichika N, Sakurai K. Pharmacological activity of difamilast, a novel PDE4 inhibitor for the topical treatment of atopic dermatitis: comparison with other PDE4 inhibitors. Presented at: American Academy of Dermatology Annual Meeting; March 1–5, 2019; Washington, DC.
    1. Hanifin JM, Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): a phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016;75:297–305. doi: 10.1016/j.jaad.2016.04.001.
    1. Saeki H, Kawashima M, Sugaya S, Oshiden K, Tsubouchi H. Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: a phase 2, randomized, double-blind, placebo-controlled study. J Dermatol. 2019;46:672–679. doi: 10.1111/1346-8138.14979.
    1. Eichenfield LF, Rosenberg N, Roth S, Davis LA, Pariser DM. Efficacy and safety of difamilast, a topical PDE4 inhibitor, in a phase 2 study of pediatric patients with atopic dermatitis. Presented at: American Academy of Dermatology Annual Meeting; March 1–5, 2019; Washington, DC.
    1. Saeki H, Baba N, Oshiden K, Abe Y, Tsubouchi H. Phase 2, randomized, double-blind, placebo-controlled, 4-week study to evaluate the safety and efficacy of OPA-15406 (difamilast), a new topical selective phosphodiesterase type-4 inhibitor, in Japanese pediatric patients aged 2–14 years with atopic dermatitis. J Dermatol. 2020;47:17–24. doi: 10.1111/1346-8138.15137.
    1. Saeki H, Baba N, Ito K, Yokota D, Tsubouchi H. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomised double-blind, vehicle-controlled trial. Br J Dermatol. 2022;186:40–49. doi: 10.1111/bjd.20655.
    1. Saeki H, Ito K, Yokota D, Tsubouchi H. Difamilast ointment in adult patients with atopic dermatitis: a phase 3 randomized double-blind vehicle-controlled trial. J Am Acad Dermatol. 2021;86:607–614. doi: 10.1016/j.jaad.2021.10.027.
    1. Saeki H. Management of atopic dermatitis in Japan. J Nippon Med Sch. 2017;84:2–11. doi: 10.1272/jnms.84.2.
    1. Futamura M, Leshem YA, Thomas KS, Nankervis H, Williams HC, Simpson EL. A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards. J Am Acad Dermatol. 2016;74:288–294. doi: 10.1016/j.jaad.2015.09.062.
    1. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
    1. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11–18. doi: 10.1034/j.1600-0625.2001.100102.x.
    1. Katayama I, Aihara M, Ohya Y, et al. Japanese guidelines for atopic dermatitis 2017. Allergol Int. 2017;66:230–247. doi: 10.1016/j.alit.2016.12.003.
    1. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) Br J Dermatol. 2015;173:1387–1399. doi: 10.1111/bjd.14164.
    1. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ, M2–124 and M2–125 study groups Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685–694. doi: 10.1016/S0140-6736(09)61255-1.
    1. Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017;77:641–9.e5. doi: 10.1016/j.jaad.2017.06.010.
    1. Reitamo S, Ortonne JP, Sand C, et al. A randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol. 2005;152:1282–1289. doi: 10.1111/j.1365-2133.2005.06592.x.
    1. Fenner J, Silverberg NB. Skin diseases associated with atopic dermatitis. Clin Dermatol. 2018;36:631–640. doi: 10.1016/j.clindermatol.2018.05.004.
    1. Furue M, Yamazaki S, Jimbow K, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol. 2011;38:310–320. doi: 10.1111/j.1346-8138.2011.01209.x.
    1. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol. 1996;35:615–619. doi: 10.1016/S0190-9622(96)90690-8.
    1. Japanese Dermatological Association. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. . [In Japanese].
    1. Damour A, Garcia M, Seneschal J, Lévêque N, Bodet C. Eczema herpeticum: clinical and pathophysiological aspects. Clin Rev Allergy Immunol. 2020;59:1–18. doi: 10.1007/s12016-019-08768-3.
    1. Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75:1393–1403. doi: 10.1007/s40265-015-0439-1.
    1. Yuan L, Dai X, Yang M, Cai Q, Shao N. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2016;11:1477–1483. doi: 10.2147/COPD.S106370.
    1. Ahluwalia J, Udkoff J, Waldman A, Borok J, Eichenfield LF. Phosphodiesterase 4 inhibitor therapies for atopic dermatitis: progress and outlook. Drugs. 2017;77:1389–1397. doi: 10.1007/s40265-017-0784-3.
    1. Guttman-Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2019;28:3–10. doi: 10.1111/exd.13817.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren